Home
overview
The revolution in drug discovery initiated by genomics, has led to a flood of new and potential drug targets. With the rapid expansion of genomics within the research and development sector, pharmaceutical and biotechnology companies are faced with new challenges: identifying novel targets, utilising genetic variation and testing of new drugs.

Pharmacogenomics & Personalised Medicine will explore the impact of genomics on drug discovery and development and the opportunities and challenges faced by the industry. The conference will focus on both the scientific and business aspects of genomics; the impact of pharmacogenomics on the pharmaceutical market, and how utilising genomics is revolutionising medicine. Different approaches for maximising bioinformatics to improve data value will also be discussed, and how investing in pharmacogenomics now, will improve medicine for the future.

This event brings together leaders in new genomic technology, where senior executives, will demonstrate effective methods to integrate the new technologies to speed up therapeutic discovery and development.

Why should you attend this event?

This comprehensive conference is organised and produced by SMi: we specialise in providing senior executives with timely, strategic and focused up to date information. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry and government figures and seek their advice and opinions. The conference will of course also be an ideal opportunity for you to network with a focused and appropriate audience, and gain up to date information regarding the future of drug discovery.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Francois Thomas

Dr Francois Thomas, VP Pharmacogenomics & Medical Affairs, Genset

9:10 PHARMACOGENETICS: OPPORTUNITIES AND CHALLENGES

Prof Klaus Lindpaintner

Prof Klaus Lindpaintner, Roche Genetics, F.Hoffman - La Roche

  • Molecular underpinnings of pharmacogenetics
  • Adapting medicines to genetic make-up
  • The challenge of clinical research in genetic epidemiology and pharmacogenetics
  • Dialogue with the public and finding societal consensus: critical issues
  • Future trends and ambitions for the industry
  • 9:40 BRIDGING THE GAP BETWEEN GENE EXPRESSION AND POPULATION GENOMICS

    Dr. Hákon Hákonarson

    Dr. Hákon Hákonarson, Chief Scientific Officer, Encode Head, Phar,acogenomics and Respiratory Research, deCODE Genetics

  • Pharmacogenomics as an integrated part of gene discovery in complex diseases
  • Integrating gene expression and genealogy-based linkage analysis
  • Drug-response phenotypes and pharmacogenomic platforms
  • Prioritising drug targets using the genealogical approach
  • Pharmacogenomics - the future of medicine
  • 10:20 SPLICE VARIANTS AS A SOURCE OF PHARMACOGENOMICS MARKERS

    Laurent Bracco

    Laurent Bracco, Vice President, Research, ExonHit Therapeutics

  • Expression profiling strategies
  • Proof-Hit: A product in cancer pharmacogenomics
  • Expression profiles and SNPs
  • Profile-Hit: A product to monitor adverse affects
  • Technical platforms
  • 11:00 Morning Coffee

    11:20 REVOLUTIONISING MEDICINE – THE POST-GENOMIC ERA

    Dr Steven Butcher

    Dr Steven Butcher, Vice President, Science, Gemini Genomics

  • The impact of clinical genomics on the elucidation of common diseases
  • The importance of maintaining high quality data flow in clinical trials
  • Challenges of high throughput screening of SNPs
  • The benefits of using clinical trials populations for genomic studies
  • Linking genomics with medicine: clinical resources for the post-genomic era
  • Drug targeting: future approaches
  • 12:00 Applying HAPÔ Technology in Drug Development and Marketing

    Dr Krishnan Nandabalan

    Dr Krishnan Nandabalan, Vice President, Product Development, Genaissance Pharmaceuticals

  • Harnessing the genetic diversity in humans by using HAPÔ technology
  • Understanding the relevance of haplotypes in Pharmacogenetic applications
  • Integrating genomic and informatic technologies to utilize HAPÔ Markers for Pharmacogenetic applications
  • Applying HAPÔ Technology in a clinical trial setting for discovery of markers to drug response
  • Utilization of HAPÔ technology in target validation and prioritization
  • Application of HAPÔ Technology in personalizing medicines
  • 12:40 Networking Lunch

    13:40 MOLECULAR EVOLUTION

    Dr Colin Higbie

    Dr Colin Higbie, President, Aptagen

  • What is Protein GenesisTM
  • Integration with Enzyme EvolutionTM
  • Advancing product development
  • Incorporation for large-scale drug target validation
  • Enhancing the functions of existing proteins and enyzmes
  • Creating and testing diversity
  • 14:20 GENOMICS AND MEDICINE

    Dr Yen Choo

    Dr Yen Choo, Research Director, Gendaq

  • Overview of the applications of genomics
  • Application of functional genomics techniques to the discovery and development of pharmaceuticals
  • High throughput methodologies for target identification and validation
  • Target validation using engineered zinc finger transcription factors
  • The future of functional genomics
  • 15:00 PHARMACOGENOMICS IN ONCOLOGY

    Dr Francois Thomas

    Dr Francois Thomas, Senior Advisor, Atlas Venture

  • Molecular profiling as a new tool for the determination of cancer classification and prognosis
  • Pharmacogenomics in the discovery and development of anticancer drugs
  • Defining the role of different genomic technologies
  • 15:40 Afternoon Tea

    16:00 THE IMPORTANCE OF PROTEOMICS TO THE PHARMACEUTICAL INDUSTRY

    Dr William Hancock

    Dr William Hancock, Vice President, Proteomics, Thermofinnigan

  • Overcoming the challenges of proteomics in personalised medicine
  • Recent developments in proteomics
  • Strategies to employ highly efficient protein separation processes
  • Characterisation with peptide mapping
  • Developing new high-throughput tools
  • 16:40 INTEGRATING BIOINFORMATICS TO ACCELERATE DRUG DISCOVERY

    Dr Christos Hatzis

    Dr Christos Hatzis, Cou-founder and Vice President, Technology Development, Silico Insights

  • Integration issues in pharmaceutical informatics
  • The interface of data analysis technologies
  • Linking bioinformatics with proteomics and high throughput screening to improve drug development
  • Utilising bioinformatics systems for high throughput data analysis
  • The effective use of bioinformatics in drug design
  • Bioinformatics & IT: enabling cutting edge drug discovery and design
  • 17:00 INTEGRATING SNPS INTO THE DRUG DISCOVERY PROCESS

    Dr Mark Brann

    Dr Mark Brann, President and Chief Scientific Officer, ACADIA Pharmaceuticals

  • Why are SNPs so important?
  • The importance of characterising SNPs and haplotypes in target genes
  • Target prioritisation: the potential of genetic polymorphisms
  • Structural pharmacogenomics: designing new and improved drugs
  • SNPs: improving public awareness
  • Advancing medicine through SNP maps
  • 17:40 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's opening Remarks

    Dr Leslie Hudson

    Dr Leslie Hudson, Senior Vice President, Global Business Management, Head, Emerging Technologies, Pharmacia

    9:10 THE BUSINESS OF GENOMICS

    Dr Mihael Polymeropoulos

    Dr Mihael Polymeropoulos, Pharmacogenomics, Novartis

  • Applications of pharmacogenomics
  • Pharmacogenetics – bridging the gap between gene discovery and drug development
  • A new way for personalised medicine – to genotype or not to genotype?
  • Targeted healthcare models
  • Ethical, legal and social implications
  • To know or not to know?
  • 9:40 IMPACT OF PHARMACOGENOMICS ON THE PHARMACEUTICAL MARKET

    Dr Matthew Kalnik

    Dr Matthew Kalnik, Executive Director, Global Prescription Business, Emerging Technologies, & Head, Pharmacogenomics, Pharmacia

  • Initiating an effective pharmacogenomics strategy
  • The direct impact on pharmaceutical R & D: target identification to validation
  • Shaping the way pharmaceuticals are commercialised
  • Improving decision making in R & D
  • Market positioning
  • Projecting the market for the future
  • 10:20 INVESTING FOR THE FUTURE

    Dr Gregory Brown

    Dr Gregory Brown, Managing Director, Head, Healthcare, Adams, Harkness and Hill

  • Building the novel venture to create real value
  • Delivering on the promise of pharmacogenomics
  • Realising the opportunities
  • Avoiding intellectual property pitfalls
  • Creating the right business model
  • Evaluating pharmacogenomics for the future
  • 11:00 Morning Coffee

    11:20 INTELLECTUAL PROPERTY ISSUES IN PHARMACOGENOMICS

    Sarah Turner

    Sarah Turner, Lawyer, Lovells

  • Current issues in genetic patenting
  • Genetic polymorphisms
  • SNPs....
  • Making the most of your IP
  • R&D and licensing agreements
  • Biotech patent litigation: current infringement and validity issues
  • 12:00 DRUG DISCOVERY TECHNOLOGY

    Dr Raymond Salemme

    Dr Raymond Salemme, President and Chief Scientific Officer, 3D Pharmaceuticals

  • Impact of pharmacogenomics on the drug discovery process
  • Technology for high-throughput drug discovery from “genomics targets”
  • The key role of informatics
  • Potential for improving the odds for successful drug development & clinical trials
  • Successful partnership strategies
  • 12:40 Networking Lunch

    14:00 THE SCIENCE AND BUSINESS OF PHARMACOGENOMICS

    Dr Mark Egerton

    Dr Mark Egerton, Vice President, Incyte Pharmaceuticals

  • Application of pharmacogenomics
  • SNP mapping – its potentials and challenges
  • DNA probe arrays for pharmacogenomic discovery
  • The challenges of data management and utility
  • Future for pharmacogenomics
  • 14:40 FROM “ONE DRUG FITS ALL” TO PERSONALISED THERAPY

    Dr Joan Soriano

    Dr Joan Soriano, Principal Epidemiologist, GlaxoSmithKline

  • Adverse drug reactions and post marketing drug safety: is pharmacogenetics the answer?
  • Focusing on drug response
  • The role of pharmacogenetics, pharmacogenomics and pharmacoepidemiology in drug surveillance and effectiveness: the individual and population approaches
  • Enhancing the value of current drugs
  • Challenging the “one drug fits all” approach
  • Limitations for pharmacogenetics and pharmacogenomics
  • 15:20 Afternoon Tea

    15:40 FROM CORPORATE STRATEGY TO ALLIANCE STRATEGY

    Anton Gueth

    Anton Gueth, Director, Alliance Management, Eli Lilly

  • Linking alliances to corporate strategy
  • Developing strategic vision
  • Setting and achieving expectations for partnerships
  • Assessing and developing winning relationships
  • 16:20 COMMERCIAL IMPLICATIONS OF PHARMACOGENETICS

    Dr Michael Luther

    Dr Michael Luther, Head, Strategy, Business & Product Development, Pharmacogenetics & Applied Diagnostics, GlaxoSmithKline

  • What are the bottlenecks in getting to market?
  • Pharmacogenetics: altering the face of pharmaceutical marketing
  • Improving intervention at earlier stages
  • Implementation of new clinical regimens
  • Novel routes for commercialisation
  • Barriers to adopting pharmacogenetics
  • 17:00 Chairman's Closing Remarks and Close of Day Two

    +

    Workshops

    Image is Everything: Public Relations and Public Perception of Biotech
    Workshop

    Image is Everything: Public Relations and Public Perception of Biotech

    The Hatton, at etc. venues
    25th September 2001
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.